Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alkermes Plc
(NQ:
ALKS
)
28.97
+0.60 (+2.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alkermes Plc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Exploring NASDAQ:ALKS's growth characteristics.
February 28, 2024
Why the growth investor may take a look at NASDAQ:ALKS.
Via
Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.
Via
Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
February 23, 2024
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.
Via
Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
February 21, 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.
Via
InvestorPlace
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
February 15, 2024
In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday.
Via
Investor's Business Daily
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Alkermes's Earnings Outlook
February 14, 2024
Via
Benzinga
Is NASDAQ:ALKS suited for growth investing?
February 07, 2024
Why the growth investor may take a look at NASDAQ:ALKS.
Via
Chartmill
NASDAQ:ALKS, an undervalued stock with good fundamentals.
January 19, 2024
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
Why the growth investor may take a look at ALKERMES PLC (NASDAQ:ALKS).
January 16, 2024
High growth, ROE and beating expectations for NASDAQ:ALKS: growth investors may appreciate this.
Via
Chartmill
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
February 13, 2024
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
February 12, 2024
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
February 06, 2024
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.
Via
Investor's Business Daily
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
February 02, 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns
Via
InvestorPlace
NASDAQ:ALKS, a growth stock which is not overvalued.
January 10, 2024
Investors seeking growth at a reasonable cost should explore NASDAQ:ALKS.
Via
Chartmill
Decoding 5 Analyst Evaluations For Alkermes
January 02, 2024
Via
Benzinga
Delving into NASDAQ:ALKS's Growth Prospects.
December 26, 2023
High growth, ROE and beating expectations for NASDAQ:ALKS: growth investors may appreciate this.
Via
Chartmill
ALKERMES PLC (NASDAQ:ALKS) showing high EPS and FCF growth while beating expectations
December 04, 2023
Why the growth investor may take a look at NASDAQ:ALKS.
Via
Chartmill
3 Top Pharma Stocks to Buy Now: February 2024
February 01, 2024
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth.
Via
InvestorPlace
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
February 01, 2024
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
January 23, 2024
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Cassava Sciences Stock Continues Showing Rising Relative Strength
January 16, 2024
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.
Via
Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy in January
January 15, 2024
These are a number of undervalued biotech companies that investor should possibly look to add to their portfolios.
Via
InvestorPlace
For those who appreciate value investing, NASDAQ:ALKS is a compelling option with its solid fundamentals.
December 28, 2023
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
Where Alkermes Stands With Analysts
November 20, 2023
Via
Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
December 20, 2023
Looking for growth without the hefty price tag? Consider ALKERMES PLC (NASDAQ:ALKS).
Via
Chartmill
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
December 07, 2023
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
Uber Will Join The S&P 500 Index. The Stock Is Jumping.
December 01, 2023
The ride-hailing giant will join the index as part of a quarterly rebalancing.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
November 29, 2023
Investors seeking growth at a reasonable cost should explore NASDAQ:ALKS.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.